Summary: In this 90-participant, four-arm phase IV randomized trial in adults with type 2 diabetes, dapagliflozin plus exenatide markedly augmented beta-cell function and insulin sensitivity above either agent alone. Acutely, the beta-cell function index rose from 0.40 (placebo) to 0.65 with dapagliflozin (62% higher), 1.17 with exenatide (threefold), and 1.69 with combination (fourfold; all P<0.001 vs placebo). These are mechanistic surrogate outcomes, not glycaemic or clinical endpoints.
PICO Summary
| Element | Detail |
|---|---|
| Population | 90 adults with type 2 diabetes; phase IV randomized clinical trial (single-centre, USA), assessed by 180-minute OGTT after a single dose (acute) and after 1 and 4 months of therapy. |
| Intervention | Dapagliflozin plus exenatide combination (n=25); also dapagliflozin alone (n=25) and exenatide alone (n=25) as active arms. |
| Comparison | Placebo (n=15), with the two monotherapy arms serving as internal comparators for the combination. |
| Outcome | Acute beta-cell function index: placebo 0.40±0.04; dapagliflozin 0.65±0.10 (62% higher, P<0.05); exenatide 1.17±0.22 (threefold); combination 1.69±0.12 (fourfold) (all P<0.001 vs placebo). Acute corrected Matsuda index (insulin sensitivity): dapagliflozin 2.29±0.33, exenatide 2.03±0.12, combination 2.36±0.14, all higher than placebo 1.63±0.36 (P<0.05). Over 1 and 4 months, beta-cell function and insulin sensitivity rose further with the monotherapies; the combination sustained but did not increase further. No 95% confidence intervals, absolute risk reduction, NNT, or clinical endpoints (HbA1c, events) were reported for these indices. |
Dapagliflozin + exenatide and beta-cell function
Phase IV RCT · type 2 diabetes · 4 months
Adding exenatide to dapagliflozin raised the acute beta-cell function index to roughly fourfold placebo, more than either agent alone. All outcomes are surrogate OGTT indices, not glycaemic or clinical endpoints.
Expert Commentary
This is a mechanistically rich phase IV randomized trial that supports a real verdict: adding a GLP-1 receptor agonist to an SGLT2 inhibitor produces a larger acute gain in beta-cell function than either drug alone, with the combination index reaching roughly fourfold the placebo value. Insulin sensitivity, corrected for the glycosuria that distorts the Matsuda index under SGLT2 inhibition, was also improved across all active arms. The findings are biologically coherent and consistent with the complementary actions of the two classes. The principal limitation is that every reported endpoint is a surrogate derived from oral glucose tolerance testing rather than a glycaemic or hard clinical outcome, and the sample is small, single-centre, and short in duration, so durability and translation to HbA1c or event reduction remain unproven here. The unusual time course, where monotherapies kept rising at 1 and 4 months while the combination plateaued, also warrants cautious interpretation rather than an assumption of unlimited additive benefit. Can I use this with my patients? Not yet as a reason to combine these agents purely for beta-cell preservation; for a person with type 2 diabetes already needing both classes for glycaemic or cardiorenal indications, it is reassuring mechanistic support rather than new prescribing guidance. Future work should test whether these surrogate gains translate into durable glycaemic control in a larger, multi-centre cohort.
References
Triplitt C, Cersosimo E, Alatrach M, et al. Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes. Diabetes Care. 2025;48(9):1545-1552. doi:10.2337/dc25-0490